Clinical Trial Finder

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

ClinicalTrials.gov ID: NCT03853798

Summary

This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.

Conditions

Pyruvate Kinase Deficiency

Recruitment Status

Active not recruiting

Details

Eligibility Criteria


Inclusion Criteria:

- Be willing and able to comply with study visits and procedures;

- Have signed written informed consent prior to participating in this extension study;

- Have completed either antecedent study AG348-C-006 or AG348-C-007 through the Part 2
Week 24 Visit;

- Cohorts 2 and 3: Have demonstrated clinical benefit from AG-348 treatment in the
antecedent study, in the opinion of the Investigator;

- For women of reproductive potential, have a negative pregnancy test during screening;

- For women of reproductive potential as well as men with partners who are women of
reproductive potential, be abstinent as part of their usual lifestyle, or agree to use
2 forms of contraception, 1 of which must be considered highly effective, from the
time of giving informed consent, during the study, and for 28 days following the last
dose of study drug for women and 90 days following the last dose of study drug for
men.

Exclusion Criteria:

- Have a significant medical condition (including clinically significant laboratory
abnormality) that developed during his/her antecedent AG- 348 study that confers an
unacceptable risk to participating in this extension study, that could confound the
interpretation of the study data, and/or that compromises the ability of the
participant to complete study visits and procedures.

- Are currently pregnant or breastfeeding.

- Have a splenectomy scheduled during the study treatment period.

- Meet the withdrawal criteria of his/her antecedent AG-348 study during screening of
this extension study.

- Are currently receiving medications that are strong inhibitors of cytochrome P450
(CYP)3A4 that have not been stopped for a duration of at least 5 days or a time frame
equivalent to 5 half-lives (whichever is longer) before start of study drug; or strong
inducers of CYP3A4 that have not been stopped for a duration of at least 28 days or a
time frame equivalent to 5 half-lives (whichever is longer) before start of study drug
on this extension study.

- Have received anabolic steroids, including testosterone preparations, within 28 days
prior to start of study drug on this extension study.

- Have received hematopoietic stimulating agents (eg, erythropoietins, granulocyte
colony stimulating factors, thrombopoietins) within 28 days prior to start of study
drug on this extension study.

- Have exposure to any investigational drug other than AG-348, device, or procedure
within 3 months prior to start of study drug on this extension study.

Intervention

Intervention Type

Drug

Intervention Name

AG-348

Phase

Phase 3

Gender

All

Minimum Age

18 Years

Maximum Age

N/A

Download Date

November 30, 2021

Principal Investigator

Rachael Grace

Primary Contact Information

Rachael Grace, MD
617-919-2144
rachael.grace@childrens.harvard.edu


For more information and to contact the study team:









For more information on this trial, visit clinicaltrials.gov.

The commitment and compassion with which we care for all children and families is matched only by the pioneering spirit of discovery and innovation that drives us to think differently, to find answers, and to build a better tomorrow for children everywhere.

Kevin B. Churchwell, President and CEO

Connect with Boston Children's Hospital